Sponsor Dossier
Takeda Pharmaceuticals
Sponsor Dossier for Takeda Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADCETRIS
- Brand: ADVATE
- Brand: ADYNOVATE
- Brand: ADZYNMA
- Brand: AGRYLIN
- Brand: ALUNBRIG
- Brand: CEPROTIN
- Brand: CINRYZE
- Device (sponsor): Syringe, general-purpose
- Device (sponsor): Medication transfer set
- Device (sponsor): Subcutaneous/intramuscular injection set, medicated
- Device (sponsor): Electric infusion pump administration set
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): General laboratoryware IVDs
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Syringe, general-purpose
- Device (sponsor): Medicine administration kit, percutaneous, non-medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, non-medicated, single-use
About
Takeda Pharmaceuticals is an Australian Private Company with ABN 71095610870, registered in NSW. The company is Active and registered for GST from 16 January 2001.
Portfolio
Takeda Pharmaceuticals has 35 brands on the ARTG, of which 34 are indexable. 30 brands have Product Information on file, 11 brands have at least one PBS-listed item, 18 brands have PBAC outcomes on record, and 16 brands have AusPARs on record.
Therapeutic focus —
Haematology: 11 brands — Oncology: 6 brands — Immunology: 5 brands — Gastroenterology: 4 brands — Neurology: 3 brands — Infectious Disease: 2 brands — Rare Disease: 2 brands — Endocrinology: 2 brands
PBS footprint
11 brands in the Takeda Pharmaceuticals portfolio have at least one PBS-listed item, with the latest PBS schedule date touched on 1 May 2026.
Regulatory activity
The most recent PBAC outcome was recorded on 1 July 2025, with 18 brands holding PBAC outcomes on record. The most recent AusPAR was issued on 1 October 2024, with 16 brands holding AusPARs on record.